Term Infants Fed a Partially Hydrolyzed Whey Protein-Based Formula
- Conditions
- Gastro-Intestinal Tolerance
- Interventions
- Other: Study Infant Formula
- Registration Number
- NCT04934397
- Lead Sponsor
- Abbott Nutrition
- Brief Summary
To assess the effects of partially hydrolyzed whey protein-based infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 18
- Participant is judged to be in good health as determined from participant's medical history by parent report
- Participant is a singleton from a full-term birth with a gestational age of 37-42 weeks
- Participant's birth weight was >= 2490 g (~5 lbs. 8 oz.)
- Participant is identified by parents as very fussy or extremely fussy on current formula in the Baseline Tolerance Evaluation
- Participant is exclusively formula-fed at time of study entry and Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study, unless instructed otherwise by their healthcare professional
- Parent(s) of participants confirm their intention not to administer vitamin, mineral, human milk oligosaccharides (HMO), prebiotic(s), or probiotic(s) supplements (with the exception of vitamin D supplements if instructed by their healthcare professional), non-study formula, foods, juices, or other sources of nutrition to their infant from enrollment through the duration of the study
- Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study
- An adverse maternal, fetal, or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. This includes but is not limited to suspected maternal substance abuse.
- Participant is taking and plans to continue taking medications (including OTC, such as Mylicon® for gas), home remedies (such as juice for constipation), herbal preparations, or rehydration fluids that might affect GI tolerance.
- Participant participates in another study that has not been approved as a concomitant study.
- Participant has been fed a formula containing greater than two HMOs prior to study enrollment.
- Participant has been fed an extensively hydrolyzed, amino acid based, or preterm formula within 14 days prior to enrollment and/or extensively hydrolyzed, amino acid based, or preterm formula has been recommended by the physician.
- Participant has an allergy or intolerance to any ingredient in the study product
- Participant has been treated with antibiotics within 7 days prior to enrollment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Study Infant Formula Study Infant Formula Feed ad libitum during study period
- Primary Outcome Measures
Name Time Method Fussiness Baseline to Study Day (SDAY) 2 Absolute and % change in fussiness severity reported from Daily Tolerance Diary
- Secondary Outcome Measures
Name Time Method Gastrointestinal Tolerance Baseline to SDAY 28 Parent Completed Diary
Stool Baseline to SDAY 28 Parent Completed Diary
Trial Locations
- Locations (14)
MedPharmics
🇺🇸Covington, Louisiana, United States
Coastal Pediatric Research
🇺🇸Charleston, South Carolina, United States
AVIATI Healthcare & Clinical Research
🇺🇸Memphis, Tennessee, United States
Midsouth Center for Clinical Research
🇺🇸Memphis, Tennessee, United States
DCOL Center for Clinical Research
🇺🇸Longview, Texas, United States
Leavitt Clinical Research
🇺🇸Idaho Falls, Idaho, United States
Alivation Research
🇺🇸Lincoln, Nebraska, United States
Southeastern Pediatric Associates
🇺🇸Dothan, Alabama, United States
ClinOhio Research Services
🇺🇸Columbus, Ohio, United States
Dayton Clinical Research
🇺🇸Dayton, Ohio, United States
Institute of Clinical Research
🇺🇸Mentor, Ohio, United States
Clear Lake Specialties
🇺🇸Webster, Texas, United States
ASCLEPES Research Centers
🇺🇸Spring Hill, Florida, United States
Clinical Research Prime
🇺🇸Idaho Falls, Idaho, United States